Detalhe da pesquisa
1.
The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
Neuroendocrinology
; 106(1): 58-73, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-28226315
2.
The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
Neuroendocrinology
; 106(1): 1-19, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-27871087
3.
GSK3α/ß: A Novel Therapeutic Target for Neuroendocrine Tumors.
Neuroendocrinology
; 106(4): 335-351, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-28968593
4.
Comparative Genomics and Transcriptome Profiling in Primary Aldosteronism.
Int J Mol Sci
; 19(4)2018 Apr 09.
Artigo
Inglês
| MEDLINE | ID: mdl-29642543
5.
Primary Aldosteronism: KCNJ5 Mutations and Adrenocortical Cell Growth.
Hypertension
; 74(4): 809-816, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31446799
6.
Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures.
Endocrinology
; 160(11): 2600-2617, 2019 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31322702
7.
The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance.
Endocr Relat Cancer
; 25(10): 893-908, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-29895527
8.
Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors.
Endocr Relat Cancer
; 25(5): 547-560, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29563190
9.
The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.
PLoS One
; 12(5): e0178375, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28542590
10.
The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
PLoS One
; 12(8): e0182852, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28800359
11.
Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways.
PLoS One
; 10(12): e0143830, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-26636335